J&J first-quarter revenue misses as Stelara sales disappoint
(Reuters) -Johnson & Johnson reported quarterly revenue below analysts\’ estimates as sales from its blockbuster psoriasis drug Stelara, which is expected to face competition from biosimilar versions in some markets later this year, fell short of expectations.